Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human epidermal transglutaminase.

L A Goldsmith

    The Journal of Investigative Dermatology
    |June 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Epidermal transglutaminase (eTG) is crucial for skin barrier function. Researchers found that solvents and chemicals can enhance eTG activity, suggesting potential therapeutic strategies for skin diseases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The essential role of dermatology publications in enhancing professional diversity, equity, and inclusion.

    Clinics in dermatology·2022
    Same author

    The essential role of dermatology publications in enhancing professional diversity, equity and inclusion.

    The British journal of dermatology·2021
    Same author

    Dermatological education for the 21st century: prioritizing diversity.

    The British journal of dermatology·2020
    Same author

    Human epidermal transglutaminase.

    The Journal of investigative dermatology·2010
    Same author

    The polypeptide composition of epidermal prekeratin.

    Biochimica et biophysica acta·2009
    Same author

    What is the pathogenesis of acne?

    Experimental dermatology·2005
    Same journal

    An Integrated Skin Cell Atlas Decodes the Pilosebaceous Unit.

    The Journal of investigative dermatology·2026
    Same journal

    Residual CSB activity explains mild UV-sensitive syndrome phenotype caused by CSB mutations.

    The Journal of investigative dermatology·2026
    Same journal

    Charting a new melanoma risk factor: Satellite Naevus Prevalence in High-Risk and Population-Based Cohorts.

    The Journal of investigative dermatology·2026
    Same journal

    Human keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris.

    The Journal of investigative dermatology·2026
    Same journal

    Merkel cells attenuate autoantigen-specific T cell driven skin inflammation in mice associated with reduced neutrophil recruitment.

    The Journal of investigative dermatology·2026
    Same journal

    The response of human melanocytic nevi to simulated solar radiation assessed by single-nucleus RNA sequencing of frozen tissue.

    The Journal of investigative dermatology·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Dermatology
    • Enzymology

    Background:

    • Epidermal transglutaminase (eTG) plays a vital role in epidermal terminal differentiation.
    • Understanding eTG's structure and activity is key to controlling its function.
    • eTG requires calcium and a free sulfhydryl group for activity.

    Purpose of the Study:

    • To investigate the structural consequences and activity modulation of epidermal transglutaminase.
    • To explore methods for altering eTG function for potential therapeutic applications in skin diseases.

    Main Methods:

    • Purification and characterization of human epidermal transglutaminase.
    • Treatment with organic solvents, chaotropic reagents, and heat to assess activity changes.
    • Analysis of structural and immunological properties using gel-filtration and SDS-electrophoresis.

    Related Experiment Videos

  • Development of monoclonal antibodies for detailed structural analysis.

    • Main Results:

    • Purified eTG activity increased significantly after treatment with organic solvents (e.g., DMSO), heat, and chaotropic reagents (e.g., NaSCN).
    • Enhanced eTG showed altered gel-filtration characteristics without major molecular weight or immunological changes.
    • Monoclonal antibodies are being developed to analyze structural activation and masked antigenic sites.

    Conclusions:

    • Solvents, chemicals, and drugs can modulate epidermal transglutaminase activity.
    • This modulation offers potential for developing safe in vivo therapeutic strategies for epidermal diseases.
    • Further research with monoclonal antibodies will elucidate eTG's structural activation and antigenic sites.